Conference Call Scheduled for 4:30 PM Eastern Time Today WALTHAM, Mass., May 5, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today provided a business update and reported financial results for the first quarter ended March […]
Financial
VESTECK, Inc. Expands Scientific Advisory Board
WEST CHESTER, Pa., May 6, 2022 /PRNewswire/ — VESTECK, Inc. is pleased to announce the expansion of their Scientific Advisory Board with the addition of Dr. Dai Yamanouchi. Dr Yamanouchi, a Vascular Surgeon, is an Associate Professor at the University of Wisconsin School of Medicine and Adjunct Professor at Tokyo Medical and Dental University also […]
Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements Maintains strong financial position while advancing and expanding development portfolio Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., May 05, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […]
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates
Announced positive topline results from Phase 2 SEISMiC study of istaroxime in early cardiogenic shock Late-breaker presentation of additional SEISMiC study results at the European Society of Cardiology (ESC) Heart Failure Conference. Management to host investor call following the presentation on May 23 WARRINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) […]
Modular Devices Announces Acquisition of Cardiac Services Mobile
INDIANAPOLIS–(BUSINESS WIRE)–Modular Devices Acquisition, LLC (Modular Devices), a leading provider of mobile cath labs and mobile cleanrooms, today announced the acquisition of Cardiac Services Mobile, Inc. (Cardiac Services Mobile), a mobile cath lab company out of Nashville, TN that serves the US markets. The acquisition builds on Modular Devices’ position […]
Athersys Reports First Quarter 2022 Results
Management to host conference call following announcement of Phase 2/3 TREASURE data in May CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2022. In anticipation of the announcement in May of topline data from Athersys’ partner, HEALIOS K.K. (Healios), for its […]
BD REPORTS SECOND QUARTER FISCAL 2022 FINANCIAL RESULTS
Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline in worldwide COVID-only testing revenues to $214 million from $474 million in the prior year GAAP diluted EPS of $1.50; adjusted diluted EPS of $3.18 Company raises mid-point of […]
Inari Medical Reports First Quarter 2022 Financial Results
IRVINE, Calif., May 04, 2022 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2022. First Quarter Revenue […]
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Texas, May 05, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update on key milestones. “We plan to resubmit our New Drug Application (NDA) for […]
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update
–Completed sale to Sentynl Therapeutics of BridgeBio’s NULIBRY™ (Fosdenopterin) for Injection –Updated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib in oncology indications in the U.S.; BridgeBio is eligible to receive regulatory and commercial milestone payments as well as tiered royalties on adjusted net sales from Helsinn –Released […]



